93 related articles for article (PubMed ID: 6792664)
1. [Cost effectiveness of pneumococcal vaccine (author's transl)].
Levy E
Rev Epidemiol Sante Publique; 1981; 29(2):133-53. PubMed ID: 6792664
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of vaccination against pneumococcal pneumonia.
Willems JS; Sanders CR; Riddiough MA; Bell JC
N Engl J Med; 1980 Sep; 303(10):553-9. PubMed ID: 6772950
[TBL] [Abstract][Full Text] [Related]
3. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
6. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
Postma MJ; Heijnen ML; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
[TBL] [Abstract][Full Text] [Related]
7. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
Ortqvist A; Jönsson B; Baltussen R; Ament A
Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
[TBL] [Abstract][Full Text] [Related]
8. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs.
Weycker D; Richardson E; Oster G
Am J Manag Care; 2000 Jul; 6(10 Suppl):S526-35. PubMed ID: 11183904
[TBL] [Abstract][Full Text] [Related]
9. [The cost-effectiveness of pneumococcal vaccination in Catalonia].
Plans Rubió P; Garrido Morales P; Salleras Sanmartí L
Rev Esp Salud Publica; 1995; 69(5):409-17. PubMed ID: 8564860
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
Fedson DS
Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
Postma MJ; Heijnen ML; Beutels P; Jager JC
Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
13. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
Silfverdal SA; Berg S; Hemlin C; Jokinen I
Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
[TBL] [Abstract][Full Text] [Related]
14. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
[TBL] [Abstract][Full Text] [Related]
15. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
De Graeve D; Verhaegen J; Ament A; Baltussen R
Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Marchetti M; Colombo GL
Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
[TBL] [Abstract][Full Text] [Related]
17. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
Simberkoff MS
Semin Respir Infect; 1993 Dec; 8(4):294-9. PubMed ID: 7938926
[TBL] [Abstract][Full Text] [Related]
19. Cost benefits of targeting the pneumococcal vaccination program to the elderly population in Taiwan.
Chen YH; Yang GY; Loh CH; Liou SH; Su WL; Lin SH; Chou CC
Am J Infect Control; 2006 Nov; 34(9):597-9. PubMed ID: 17097456
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of pneumococcal conjugate vaccination in Finland.
Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
